IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Publication
, Conference
Cortes, JE; Traer, E; Wang, ES; Erba, HP; Blum, W; Arana-Yi, C; Sloss, CM; Culm-Merdek, K; Towles, J; Zweidler-McKay, PA; DeAngelo, DJ
Published in: BLOOD
December 7, 2017
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 7, 2017
Volume
130
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
59th Annual Meeting of the American-Society-of-Hematology (ASH)
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Cortes, J. E., Traer, E., Wang, E. S., Erba, H. P., Blum, W., Arana-Yi, C., … DeAngelo, D. J. (2017). IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. In BLOOD (Vol. 130). Atlanta, GA: AMER SOC HEMATOLOGY.
Cortes, Jorge E., Elie Traer, Eunice S. Wang, Harry P. Erba, William Blum, Cecilia Arana-Yi, Callum M. Sloss, et al. “IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia.” In BLOOD, Vol. 130. AMER SOC HEMATOLOGY, 2017.
Cortes JE, Traer E, Wang ES, Erba HP, Blum W, Arana-Yi C, et al. IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. In: BLOOD. AMER SOC HEMATOLOGY; 2017.
Cortes, Jorge E., et al. “IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia.” BLOOD, vol. 130, AMER SOC HEMATOLOGY, 2017.
Cortes JE, Traer E, Wang ES, Erba HP, Blum W, Arana-Yi C, Sloss CM, Culm-Merdek K, Towles J, Zweidler-McKay PA, DeAngelo DJ. IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. BLOOD. AMER SOC HEMATOLOGY; 2017.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 7, 2017
Volume
130
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
59th Annual Meeting of the American-Society-of-Hematology (ASH)
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology